Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) —  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the company’s COVID-19 oral tablet vaccine development program at the International Congress of Mucosal Immunology 2022, which is being held in Seattle July 16 to 20, 2022.

Presentation Information:

Title: Oral Tablet Vaccination to SARS-CoV-2 Induces Pan-coronavirus Nasal IgA Responses in Humans
Speaker: Dr. Sean Tucker
Date: Monday, July 18, 2022
Time: 11:00 a.m. PT / 2:00 p.m. ET

Title: Mucosal rAd5 Immunization against SARS-CoV-2 Spike Elicits Cross-Reactive Nasal and Serum Neutralizing Antibodies and Protects Against Beta Variant Challenge in Non-Human Primates
Speaker: Dr. Rebecca Flitter
Date: Monday, July 18, 2022
Time: 11:00 a.m. PT / 2:00 p.m. ET

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts              
  

Vaxart Media Relations:  Investor Relations:     
Mark Herr    Andrew Blazier
Vaxart, Inc.    FINN Partners
mherr@vaxart.com IR@Vaxart.com
(203) 517-8957     (646) 871-8486   

Staff

Recent Posts

cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

Charlotte, North Carolina--(Newsfile Corp. - April 10, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

3 hours ago

Laboratory Services Cooperative Notifies Individuals of Security Incident

SEATTLE, April 10, 2025 /PRNewswire/ -- Laboratory Services Cooperative (LSC), a non-profit organization based in…

3 hours ago

True Dental Care Provides Notice of Data Incident

SUWANEE, Ga., April 10, 2025 /PRNewswire/ -- On February 3, 2025, True Dental Care ("True…

3 hours ago

Groundbreaking Study Explores THC Beverages as a Wellness Alternative to Alcohol

PHILADELPHIA, April 10, 2025 /PRNewswire/ -- MoreBetter, a leader in Real-World-Data collection and research, has…

3 hours ago

Launch and Learn: Media Invited to Science Webinar on NASA’s SpaceX CRS-32 Mission

Register today for the April 16 webinar, featuring cutting-edge biotech, plant biology, and airborne pollutant…

3 hours ago

Global Pharma Organization Implements Advanced Signals as Part of LifeSphere Safety Platform

BOSTON, April 10, 2025 /PRNewswire/ -- ArisGlobal, an innovative technology company at the forefront of life…

9 hours ago